A Randomized, Double-Masked, Parallel- Group, Phase 2a Dry Eye Disease Clinical Trial to Evaluate the Safety and Efficacy of Topical Ocular ADX-102, a Novel Aldehyde Sequestering Agent

被引：0
|
作者：
Clark, David [1 ]
Ousler, George W. [2 ]
Hollander, David [2 ]
Brady, Todd [1 ]
机构：
[1] Aldeyra Therapeut, Clin, Lexington, MA USA
[2] Ora Inc, Andover, MA USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2018年 / 59卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
1967
引用
收藏
页数：2
相关论文
共 44 条
  • [31] Efficacy and Safety of HD-6277, a Novel GPR40 Agonist, in Patients with Type 2 Diabetes-A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Trial
    Lee, Yong-Ho
    Min, Kyungwan
    Hong, Jun Hwa
    Lim, Soo
    Yu, Jaemyung
    Chung, Choon H.
    Moon, Jun Sung
    Won, Jong Chul
    Ahn, Chul Woo
    Lee, Jie-Eun
    Kim, Tae Nyun
    Lee, Byung-Wan
    DIABETES, 2024, 73
  • [32] Efficacy and safety of MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to retinitis pigmentosa: A phase 2b randomized, sham-controlled, multi-center, multi-dose, double-masked clinical trial (RESTORE)
    Boyer, David
    Bergstrom, Lance
    Emanuelli, Andres
    Gonzalez, Victor
    Wykoff, Charles
    Gupta, Sunil
    Liao, David
    Zak, Vitaliy
    Chavala, Sai
    Mohanty, Samar
    Bataybal, Subrata
    Piltz-Seymour, Jody
    Ayyagari, Ananta
    Koester, John
    Osborne, Aaron
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [33] A prospective, randomized, open label, parallel group, comparative clinical trial to evaluate the safety and efficacy of combination of herbal oral capsule and rectal medication to improve gut health of type 2 diabetic patients having chronic kidney disease (CKD)
    Patankar, Suresh
    Gorde, Anupama
    Patankar, Sagar
    Raje, Rajesh
    Devanpally, Chandu
    Ausekar, Pranjal
    Patil, Gaurav
    Chitale, Shraddha
    JOURNAL OF AYURVEDA AND INTEGRATIVE MEDICINE, 2025, 16 (02)
  • [34] Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study
    Tatsuo Hosoya
    Takafumi Sano
    Tomomitsu Sasaki
    Masahiko Fushimi
    Tetsuo Ohashi
    Clinical and Experimental Nephrology, 2020, 24 : 53 - 61
  • [35] Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study
    Hosoya, Tatsuo
    Sano, Takafumi
    Sasaki, Tomomitsu
    Fushimi, Masahiko
    Ohashi, Tetsuo
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2020, 24 (SUPPL 1) : 53 - 61
  • [36] A Phase 2, Randomized, Double-Blind, Parallel-Group, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety of a Novel Potassium-Competitive Acid Blocker (P-CAB) TAK-438 in Patients With Erosive Esophagitis
    Chiba, Tsutomu
    Sakurai, Yuuichi
    Nishimura, Akira
    Hiramatsu, Naoki
    Umegaki, Eiji
    Iwakiri, Katsuhiko
    Ashida, Kiyoshi
    GASTROENTEROLOGY, 2013, 144 (05) : S564 - S565
  • [37] A phase 2a, randomized, double-blind, placebo-controlled, three-arm, parallel-group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes
    Saxena, Aditi R.
    Lyle, Stephanie-An
    Khavandi, Kaivan
    Qiu, Ruolun
    Whitlock, Mark
    Esler, William P.
    Kim, Albert M.
    DIABETES OBESITY & METABOLISM, 2023, 25 (04): : 992 - 1001
  • [38] Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study
    Hosoya, Tatsuo
    Sano, Takafumi
    Sasaki, Tomomitsu
    Fushimi, Masahiko
    Ohashi, Tetsuo
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2020, 24 (SUPPL 1) : 44 - 52
  • [39] Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study
    Tatsuo Hosoya
    Takafumi Sano
    Tomomitsu Sasaki
    Masahiko Fushimi
    Tetsuo Ohashi
    Clinical and Experimental Nephrology, 2020, 24 : 44 - 52
  • [40] Safety, tolerability and preliminary efficacy results of ORB-CEL-M - a novel mesenchymal stromal cell therapy - in diabetic kidney disease: The multicenter, randomized, placebo-controlled, phase-1b/2a NEPHSTROM clinical trial
    Remuzzi, G.
    Griffin, M.
    Cockwell, P.
    Maxwell, P.
    Perico, N.
    Ruggenenti, P.
    Introna, M.
    Finnerty, A.
    Smythe, J.
    Fibbe, W.
    Elliman, S.
    O'Brien, T.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2024, 193 : S172 - S172
12345